Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo‐controlled multiomics‐based clinical trial
Journal of Pediatric Gastroenterology and Nutrition · 2025
DOI: 10.1002/jpn3.70154 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Fernanda Cristofori und 11 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Department of Medicine, Pediatric Section, Children's Hospital' Giovanni XXIII', University of Bari Aldo Moro, Bari, Italy. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Gastrointestinal Microbiome, Butyric Acid, Dietary Supplements. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: None.
Abstract (Originalsprache)
Objective
Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, and treatment involves nonpharmacological and pharmacological therapies, even if there is no optimal therapy. This randomized, placebo‐controlled, double‐blind trial aimed to evaluate the efficacy of calcium butyrate supplementation in reducing IBS symptoms and to assess its effects on gut microbiota composition and relative metabolic profiles through a multiomics approach.
Methods
Children aged 4–17 years with IBS diagnosed according to the Rome IV criteria were randomized to receive either a formulation based on calcium butyrate (500 mg/day) or placebo for 8 weeks, followed by a 4‐week follow‐up period. Clinical assessments included the visual analogue scale (VAS) and gastrointestinal symptom rating scale (GSRS). Fecal samples were analyzed via 16S metataxonomics and targeted/untargeted metabolomics. The primary outcome was an ≥50% reduction in the VAS scores. Secondary outcomes included microbiota composition changes and metabolite profile alterations.
Results
Fifty‐one children were enrolled. Treatment success was significantly higher in the butyrate group (73% vs. 3.8%, p < 0.0001). VAS and GSRS scores were significantly reduced in butyrate‐treated patients at the end of treatment and postwashout. Metataxonomic analysis revealed increased short chain fatty acids‐producing bacteria, including Lachnospiraceae and Ruminococcus gauvreauii , while pro‐inflammatory taxa such as Ruminococcus gnavus decreased. Metabolomics confirmed significant changes in SCFA and VOCs, supporting microbiota modulation.
Discussion
Calcium butyrate supplementation effectively reduced IBS symptoms and induced beneficial microbiota and metabolic shifts in pediatric patients. These findings support butyrate as a potential therapy in pediatric IBS, warranting further large‐scale investigations to confirm efficacy and optimize dosing strategies. Clinical Trial Identification Number Study registered on: https://ClinicalTrials.gov . Number of registration: NCT04566679 Date of registration: 28/09/2020. Date of first enrollment of patients: 01/05/2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Department of Medicine, Pediatric Section, Children's Hospital' Giovanni XXIII', University of Bari Aldo Moro, Bari, Italy.
- Department of Soil, Plant and Food Sciences, University of Bari Aldo Moro, Bari, Italy.
- Department of Agricultural, Forest and Food Sciences, University of Turin, Grugliasco, Italy.
ORCID-Profile: Fernanda Cristofori, Francesco Maria Calabrese
Förderung
- None
Zitieren
APA
Cristofori, F., Calabrese, F. M., Iacobellis, I., Santamaria, M., Celano, G., Ferrocino, I., Di Sabato, E., Pergola, R., Dargenio, V. N., Paulucci, L., De Angelis, M., & Francavilla, R. (2025). Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo‐controlled multiomics‐based clinical trial. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70154
Vancouver
Cristofori F, Calabrese FM, Iacobellis I, Santamaria M, Celano G, Ferrocino I, et al. Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo‐controlled multiomics‐based clinical trial. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70154
BibTeX
@article{Cristofori2025,
author = {Cristofori, Fernanda and Calabrese, Francesco Maria and Iacobellis, Ilaria and Santamaria, Monica and Celano, Giuseppe and Ferrocino, Ilario and Di Sabato, Emanuela and Pergola, Rocco and Dargenio, Vanessa N and Paulucci, Leonardo and De Angelis, Maria and Francavilla, Ruggiero},
title = {Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo‐controlled multiomics‐based clinical trial},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
doi = {10.1002/jpn3.70154}
}
EUVIMED